Five-year data supported the long-term safety and effectiveness of transvenous phrenic nerve stimulation (TPNS) for central sleep apnea (CSA), investigators said. CSA severity decreased in patients ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window HOUSTON -- Use of transvenous phrenic nerve stimulation (TPNS) ...

Researchers examined patients with central sleep apnea after 5 years of treatment with transvenous phrenic nerve stimulation therapy. This article is part of MPR’s coverage of the CHEST Virtual 2020 ...

Please provide your email address to receive an email when new articles are posted on . Five-year data show sustained safety and efficacy outcomes after implantation of a transvenous phrenic nerve ...

MINNETONKA, Minn., July 10, 2019 /PRNewswire/ -- Respicardia, Inc., the manufacturer of the only FDA-approved active implantable device for the treatment of central sleep apnea (CSA), today announced ...

LOWER MERION – Bryn Mawr Hospital, part of Main Line Health’s Lankenau Heart Institute, on Aug. 18 became the first site in the world to successfully enroll a patient and complete the protocol in ...

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL ® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the United States Food and ...

ZOLL Announces Five-Year Study Confirming Safety, Efficacy and Beneficial Effects of Long-Term Transvenous Phrenic Nerve Stimulation (the remedē System) Study results published in the peer-reviewed ...

A new clinical practice guideline developed by a task force of the American Academy of Sleep Medicine provides updated recommendations for the treatment of central sleep apnea. Available online as an ...

The phrenic nerve controls the diaphragm, the dome-shaped muscle that is primarily responsible for breathing. Contraction of the diaphragm expands the lungs and draws air into them. The phrenic nerve ...